Disease on EC 1.1.1.41 - isocitrate dehydrogenase (NAD+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Inactivation of metabolic enzymes by photo-treatment with zinc meta N-methylpyridylporphyrin.
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer.
Arthritis
Oxidative state and oxidative metabolism of the heart from rats with adjuvant-induced arthritis.
Astrocytoma
Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry.
Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.
Exploiting Metabolic Differences in Glioma Therapy.
Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas.
KIAA1549-BRAF Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults.
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Molecular subclassification of diffuse gliomas: Seeing order in the chaos.
Mutant metabolic enzymes are at the origin of gliomas.
Neuronal-astrocyte metabolic interactions: understanding the transition into abnormal astrocytoma metabolism.
Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.
Promoter Methylation Analysis of IDH Genes in Human Gliomas.
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Biliary Tract Diseases
[Isocitrate dehydrogenase activity in liver and biliary tract diseases as an indicator of liver cell necrosis]
Brain Neoplasms
Cancer metabolism as a central driving force of glioma pathogenesis.
Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression.
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Isocitric dehydrogenase of the cerebrospinal fluid in brain tumours and meningitis.
Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
Recent aspects of classification and epidemiology of epilepsy-associated tumors.
Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
Breast Neoplasms
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling.
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.
[Activity of isocitrate dehydrogenase in breast cancer]
[Biochemical behavior of pyruvate kinase, LDH, isocitrate dehydrogenase and malate dehydrogenase in breast carcinomas]
Carcinogenesis
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Isocitrate dehydrogenase mutations in leukemia.
Metabolic changes in cancer: beyond the Warburg effect.
Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
Suppression of tumorigenesis in mitochondrial NADP(+)-dependent isocitrate dehydrogenase knock-out mice.
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State.
The role of NAD(+)-dependent isocitrate dehydrogenase 3 subunit ? in AFB1 induced liver lesion.
Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations.
Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells.
Carcinoma
Comparative proteomic analysis of esophageal squamous cell carcinoma.
Diphosphopyridine nucleotide specific isocitric dehydrogenase of mammalian mitochondria. II. Kinetic properties of the enzyme of the Ehrlich ascites carcinoma.
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
NAD-dependent isocitrate dehydrogenase as a novel target of tributyltin in human embryonic carcinoma cells.
Serum enzymes in disease V. Isocitric dehydrogenase, malic dehydrogenase, and glycolytic enzymes in patients with carcinoma of the breast.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Tributyltin induces G2/M cell cycle arrest via NAD(+)-dependent isocitrate dehydrogenase in human embryonic carcinoma cells.
Tributyltin induces mitochondrial fission through NAD-IDH dependent mitofusin degradation in human embryonic carcinoma cells.
[Histoenzymatic studies of carcinoma of the cervix (lactic dehydrogenase, malic dehydrogenase, isocitric dehydrogenase and succinic dehydrogenase)]
Carcinoma, Basal Cell
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
Carcinoma, Ehrlich Tumor
Enzyme activities of six different dehydrogenases in Ehrlich ascites cells measured by flow cytometry.
Carcinoma, Hepatocellular
A pilot study on the screening of primary hepatocellular carcinoma in selected high risk groups in the population using multiple tumour markers.
Chemopreventive efficacy of selenium against N-nitrosodiethylamine-induced hepatoma in albino rats.
Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients.
High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma.
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Carcinoma, Squamous Cell
Comparative proteomic analysis of esophageal squamous cell carcinoma.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
Cardiotoxicity
A possible mechanism of adriamycin cardiotoxicity. Inhibition of NADP-linked isocitrate dehydrogenase.
Cataract
[Malate dehydrogenase and TPN-specific isocitrate dehydrogenase in human cataract lenses]
Chemical and Drug Induced Liver Injury
[Activity of liver mitochondrial NAD+-dependent dehydrogenases of the krebs cycle in rats with acetaminophen-induced hepatitis developed under conditions of alimentary protein deficiency].
Cholangiocarcinoma
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Cholecystitis
HIGH SERUM TRANSAMINASE AND ISOCITRIC DEHYDROGENASE LEVELS IN A PATIENT WITH CHOLECYSTITIS AND SUBACUTE HEPATITIS.
Cholestasis
Relationship between antioxidant systems, intracellular thiols and DNA ploidy in liver of rats during experimental cirrhogenesis.
Chondroma
Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas.
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Chondrosarcoma
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Colonic Neoplasms
Targeting cancer metabolism.
Coma
Effect of total hepatectomy on selected cerebral substrates and enzymes of the glycolytic pathways and Krebs cycle.
[Changes of some energy exchange parameters in the rat heart under insulin hypoglycemia]
Cysts
Sarcocystis fusiformis: some Krebs cycle enzymes in various fractions of sarcocysts of buffalo (Bubalus bubalis).
Dehydration
Crystal structure of the monomeric isocitrate dehydrogenase in the presence of NADP+: insight into the cofactor recognition, catalysis, and evolution.
Diabetes Mellitus
Metabolism and ultrastructure in ovaries of alloxan-diabetic juvenile rats.
Diabetic Nephropathies
Effect of yam (Dioscorea cayenensis) and dasheen (Colocassia esculenta) extracts on the kidney of streptozotocin-induced diabetic rats.
Down Syndrome
Mitochondrial enzyme deficiencies in Down's syndrome.
Dystonia
[Activity of oxidative enzymes during dosed exercise in healthy persons and in persons with neurocirculatory dystonia]
Enchondromatosis
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
Endometrial Neoplasms
Biochemical changes in endometrial carcinoma and their correlation to clinical outcome and prognosis.
The effects of PGC-1? on the proliferation and energy metabolism of malignant endometrial cancer cells.
Epilepsy
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
Fatty Liver
Biochemical changes associated with the fatty liver syndrome in cows.
Prevention of CCl4-induced liver necrosis by the calcium chelator arsenazo III.
Fetal Growth Retardation
Altered expression and function of mitochondrial beta-oxidation enzymes in juvenile intrauterine-growth-retarded rat skeletal muscle.
Gallstones
Identification of Helicobacter pylori DNA in Iranian patients with gallstones.
Gastritis
Isocitrate Dehydrogenase of Helicobacter pylori Potentially Induces Humoral Immune Response in Subjects with Peptic Ulcer Disease and Gastritis.
Giant Cell Tumor of Bone
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Giant Cell Tumors
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Gingivitis
Expression of TET2 enzyme indicates enhanced epigenetic modification of cells in periodontitis.
Glioblastoma
A new functional IDH2 genetic variant is associated with the risk of lung cancer.
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Analysis of the IDH1 codon 132 mutation in brain tumors.
Cancer metabolism as a central driving force of glioma pathogenesis.
Cancer-associated IDH mutations: biomarker and therapeutic opportunities.
Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma.
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Expanding the spectrum of IDH1 mutations in gliomas.
Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Glioblastoma.
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?
High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme.
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Immunotherapy for secondary glioblastoma multiforme: toward an isocitrate dehydrogenase vaccine.
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.
Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3?
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations.
Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating ?-oxygenation pathway in colorectal cancer.
Metabolic Reprogramming in Mutant IDH1 Glioma Cells.
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Promoter Methylation Analysis of IDH Genes in Human Gliomas.
Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
Glioma
2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.
A comparative study of short- and long-TE (1) H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors.
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
A new functional IDH2 genetic variant is associated with the risk of lung cancer.
A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
A vaccine targeting mutant IDH1 induces antitumour immunity.
Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: A phantom study.
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Biomarker-driven diagnosis of diffuse gliomas.
BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Cancer metabolism as a central driving force of glioma pathogenesis.
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas.
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
DNA methylation in adult diffuse gliomas.
DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
Elevated expression of fatty acid synthase and nuclear localization of carnitine palmitoyltransferase 1C are common among human gliomas.
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Emerging interplay of genetics and epigenetics in gliomas: a new hope for targeted therapy.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging.
Expanding the spectrum of IDH1 mutations in gliomas.
Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.
Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling.
Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
FGFR-TACC gene fusions in human glioma.
Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Gene markers in brain tumors: what the epileptologist should know.
Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Glioma-derived mutations in IDH: from mechanism to potential therapy.
Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
Glioma.
Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?
Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome.
Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
IDH mutation in glioma: new insights and promises for the future.
IDH1 and IDH2 Mutations in Gliomas.
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature.
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.
IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma.
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.
IDH2 mutation in gliomas including novel mutation.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
IGFBP2 expression predicts IDH-mutant glioma patient survival.
Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Isocitrate Dehydrogenase Mutation Leads to Alteration in 3-Dimensional DNA Structure and Oncogene Activation in Gliomas.
Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Isocitrate dehydrogenase mutations in gliomas.
Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas.
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
KIAA1549-BRAF Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults.
Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3?
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations.
Low-grade gliomas.
Lower apparent diffusion coefficients indicate distinct prognosis in low-grade and high-grade glioma.
Malignant clinical features of anaplastic gliomas without IDH mutation.
Management of diffusely infiltrating glioma in the elderly.
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Metabolic Reprogramming in Mutant IDH1 Glioma Cells.
MicroRNA-183 upregulates HIF-1? by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells.
Mitochondrial dysfunction in gliomas.
Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
Molecular subclassification of diffuse gliomas: Seeing order in the chaos.
Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma.
MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.
Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor??B activation in a hypoxia?inducible factor 1?? dependent manner.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9
Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
Neuro-oncology: Five new things.
Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
New treatment paradigm for patients with anaplastic oligodendroglial tumors.
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
Novel ways to target brain tumour metabolism.
Oncometabolites: tailoring our genes.
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016.
Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation.
Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.
Protein Markers Predict Survival in Glioma Patients.
Proximity ligation assay evaluates IDH1R132H presentation in gliomas.
Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and non-neoplastic conditions.
Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Role of isocitrate dehydrogenase in glioma.
Rosette-Forming Glioneuronal Tumor Originating From the Spinal Cord: Report of 2 Cases and Literature Review.
Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated Isocitrate Dehydrogenase.
Silencing of mitochondrial NADP(+)-dependent isocitrate dehydrogenase gene enhances glioma radiosensitivity.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Targeting cancer metabolism.
Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review).
The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner.
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
The epidemiology of glioma in adults: a "state of the science" review.
The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.
Treatment of anaplastic glioma.
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
[Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
[The expression of IDH1 (R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples].
Gliosarcoma
An IDH1-mutated primary gliosarcoma: case report.
Clinicopathologic and genomic features of gliosarcomas.
Hearing Loss
SIRT3 in calorie restriction: can you hear me now?
Heart Failure
Proteomic analysis of left ventricular remodeling in an experimental model of heart failure.
Hemangioma
Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
Hematologic Neoplasms
Familial hematological malignancies: new IDH2 mutation.
IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Mathematical analysis predicts imbalanced IDH1/2 expression associates with 2-HG-inactivating ?-oxygenation pathway in colorectal cancer.
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
Hepatitis
HIGH SERUM TRANSAMINASE AND ISOCITRIC DEHYDROGENASE LEVELS IN A PATIENT WITH CHOLECYSTITIS AND SUBACUTE HEPATITIS.
Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism.
Studies on transmission of human non-A, non-B hepatitis to marmosets.
[Activity of liver mitochondrial NAD+-dependent dehydrogenases of the krebs cycle in rats with acetaminophen-induced hepatitis developed under conditions of alimentary protein deficiency].
[Behavior of serum isocitrate dehydrogenase in subjects with viral hepatitis after treatment with lysozyme]
[Study on the behavior of serum isocitrate dehydrogenase. In subjects affected by viral hepatitis]
[The value of isocitric dehydrogenase in the differential diagnosis between viral hepatitis and Weil's disease.]
Hepatitis A
Comparison of activities of isocitric dehydrogenase and glutamic-oxalacetic transaminase in serum infectious hepatitis.
Hyperhomocysteinemia
Homocysteine induces energy imbalance in rat skeletal muscle: Is creatine a protector?
Hypersensitivity
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Hypertension
Cardiac hypertrophy in spontaneously hypertensive rats.
Comparative analysis of renal protein expression in spontaneously hypertensive rat.
Hyperthyroidism
Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism.
Hypoglycemia
Cocklebur (Xanthium strumarium, L. var. strumarium) intoxication in swine: review and redefinition of the toxic principle.
Hypokinesia
[Activity of oxidative enzymes of the tricarboxylic acid cycle in the liver of rats during hypokinesia]
[Oxidative enzyme activity of the tricarboxylic acid cycle in rat skeletal muscles in hypokinesia]
Infection
Acute GB virus B infection of marmosets is accompanied by mutations in the NS5A protein.
Alterations in enzymatic activities of the intestinal mucosa during the course of Giardia lamblia infection in mice.
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.
Further investigations of race:cultivar-specific induction of enzymes related to phytoalexin biosynthesis in soybean roots following infection with Phytophthora megasperma f.sp. glycinea.
Inflammatory Bowel Diseases
Glycylprolyl-p-nitroanilidase in hepatobiliary disease.
Influenza, Human
Structural similarity between binding sites in influenza sialidase and isocitrate dehydrogenase: implications for an alternative approach to rational drug design.
Insulin Resistance
Increased obesity resistance and insulin sensitivity in mice lacking the isocitrate dehydrogenase 2 gene.
Intellectual Disability
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
isocitrate dehydrogenase (nad+) deficiency
Mitochondrial NADP(+)-Dependent Isocitrate Dehydrogenase Deficiency Exacerbates Mitochondrial and Cell Damage after Kidney Ischemia-Reperfusion Injury.
Kwashiorkor
Serum transaminases and isocitric dehydrogenase in kwashiorkor.
Leukemia
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
Genistein decreases cellular redox potential, partially suppresses cell growth in HL?60 leukemia cells and sensitizes cells to ??radiation?induced cell death.
IDH mutation in glioma: new insights and promises for the future.
Isocitrate dehydrogenase mutations in leukemia.
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Targeting cancer metabolism.
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.
[Behavior of serum isocitrate dehydrogenase in acute lymphatic leukemia of childhood]
[Research advances of IDH gene mutation and AML].
Leukemia, Myeloid
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Leukemia, Myeloid, Acute
2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
Epigenetic aberrations in myeloid malignancies (Review).
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
IDH mutations in acute myeloid leukemia.
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Isocitrate dehydrogenase mutations in myeloid malignancies.
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C?>?T have a prognostic value in acute myeloid leukemia.
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission.
Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia.
Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
[Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
[Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
Liver Diseases
An evaluation of isocitric dehydrogenase in liver disease.
Falsely normal value in fluorometric transferase screening of galactosemic blood. A cautionary note.
Serum isocitrate dehydrogenase in liver disease and some other conditions.
Serum isocitric dehydrogenase activity in the differential diagnosis of liver disease.
Serum isocitric dehydrogenase activity with particular reference to liver disease.
[SERUM ENZYMES IN THE DIAGNOSIS OF LIVER DISEASE. III. SORBITOL DEHYDROGENASE, ALDOLASES, ISOCITRIC DEHYDROGENASE AND TRANSAMINASES.]
[STUDIES ON ISOCITRIC DEHYDROGENASE IN SERUM OF LIVER DISEASES.]
[STUDIES ON SERUM ISOCITRATE DEHYDROGENASE. II. IN LIVER DISEASES.]
[Studies on the enzymatic activity value of serum isocitrate dehydrogenase in pediatrics. 3. On the enzymatic activity value of serum isocitrate dehydrogenase in liver diseases in children.]
[The diagnostic importance of isocitrate dehydrogenase and of glutathione reductase in liver diseases.]
Lung Neoplasms
Effect of mangiferin on benzo(a)pyrene induced lung carcinogenesis in experimental Swiss albino mice.
IDH-Inhibiting Small Molecule DTDQ Inhibits Migration and Invasion of A549 Human Non-Small-Cell Lung Cancer Cells via Sequential Inactivation Of ERK and P38 Signaling Pathways.
Modulation of TCA cycle enzymes and electron transport chain systems in experimental lung cancer.
Lymphoma
Myeloproliferative neoplasms: Current molecular biology and genetics.
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Lymphoma, T-Cell
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Malaria
NADP-specific isocitrate dehydrogenase from the simian malaria parasite Plasmodium knowlesi: partial purification and characterization.
Malnutrition
[Activity of amylase, lipase and isocitrate dehydrogenase enzymes in cases of proteino-caloric malnutrition]
Melanoma
5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma.
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.
Mitochondrial NADP(+)-dependent isocitrate dehydrogenase knockdown inhibits tumorigenicity of melanoma cells.
Mutational status of IDH1 in uveal melanoma.
Proteomic investigation of the sinulariolide-treated melanoma cells A375: effects on the cell apoptosis through mitochondrial-related pathway and activation of caspase cascade.
Meningitis
Isocitric dehydrogenase of the cerebrospinal fluid in brain tumours and meningitis.
Metabolic Diseases
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Microcephaly
Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase.
Mouth Neoplasms
Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.
Multiple Sclerosis
[DETERMINATION OF ISOCITRATE DEHYDROGENASE, LACTIC DEHYDROGENASE AND GLUTAMIC-OXALACETIC TRANSAMINASE IN THE CEREBROSPINAL FLUID IN MULTIPLE SCLEROSIS.]
Muscular Dystrophies
[Serum enzyme dynamics in progressive muscular dystrophies]
Muscular Dystrophy, Duchenne
[Reevaluation of serum isocitrate dehydrogenase concentration as liver function marker in patients with Duchenne muscular dystrophy]
Myelodysplastic Syndromes
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
Isocitrate dehydrogenase mutations in myeloid malignancies.
Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Myocardial Infarction
CHANGES IN SERUM ISOCITRATE DEHYDROGENASE IN MYOCARDIAL INFARCTION.
Glycylprolyl-p-nitroanilidase in hepatobiliary disease.
Resveratrol protects left ventricle by increasing adenylate kinase and isocitrate dehydrogenase activities in rats with myocardial infarction.
Myocarditis
[The effect of guanosyl-5'-monophosphate on metabolic processes in rats with experimental myocarditis]
Neoplasm, Residual
Frontline treatment of acute myeloid leukemia in adults.
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Neoplasms
2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.
5-hydroxymethylcytosine and its potential roles in development and cancer.
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
A highly facile and specific assay for cancer-causing isocitrate dehydrogenase mutant using 13C4-labeled ?-ketoglutarate and heteronuclear NMR.
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
A novel truncated form of HMGA2 in tumors of the ovaries.
A vaccine targeting mutant IDH1 induces antitumour immunity.
Aberrant IDH3? expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis.
Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.
Absence of IDH mutation in colorectal cancers with microsatellite instability.
Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.
Activated leukocyte cell adhesion molecule is expressed in neuroepithelial neoplasms and decreases with tumor malignancy, matrix metalloproteinase 2 expression, and absence of IDH1R132H mutation.
Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Astrocytic gliomas WHO grades II and III.
ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Bevacizumab and other novel therapies for recurrent oligodendroglial tumors.
Biochemical changes in endometrial carcinoma and their correlation to clinical outcome and prognosis.
Biochemical markers of central nervous system tumors measured in cerebrospinal fluid and their potential use in diagnosis and patient management: a review.
Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery.
Cancer and Altered Metabolism: Potential Importance of Hypoxia-Inducible Factor and 2-Oxoglutarate-Dependent Dioxygenases.
Cancer metabolism as a central driving force of glioma pathogenesis.
Cancer-associated IDH mutations: biomarker and therapeutic opportunities.
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Comparative proteomic analysis of esophageal squamous cell carcinoma.
Detecting isocitrate dehydrogenase gene mutations in oligodendroglial tumors using diffusion tensor imaging metrics and their correlations with proliferation and microvascular density.
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.
DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Effective use of small-interfering RNA to characterize residual B-cell non-Hodgkin lymphoma cells following chemotherapy.
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Emerging biomarkers in glioblastoma.
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Enzyme activities of six different dehydrogenases in Ehrlich ascites cells measured by flow cytometry.
Enzymes in cancer. 2. The isocitric dehydrogenase of the cerebrospinal fluid in various cancerous and noncancerous conditions.
Epigenetic aberrations in myeloid malignancies (Review).
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells.
Familial hematological malignancies: new IDH2 mutation.
Fatty acid labeling from glutamine in hypoxia can be explained by isotope exchange without net reductive IDH flux.
Fisetin modulates mitochondrial enzymes and apoptotic signals in benzo(a)pyrene-induced lung cancer.
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.
Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis.
Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Genomic profiling of lower-grade gliomas uncovers cohesive disease groups: implications for diagnosis and treatment.
Glioblastoma.
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Glioma.
Glioneuronal tumours with features of rosette-forming glioneuronal tumours of the fourth ventricle and dysembryoplastic neuroepithelial tumours: a report of three cases.
Heterogeneity of tumor-induced gene expression changes in the human metabolic network.
High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma.
HISTOCHEMICAL STUDIES ON THE LOCALIZATION OF ISOCITRIC DEHYDROGENASE IN HUMAN TUMORS.
Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.
Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate.
Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome.
IDH Mutation Detection in Formalin-Fixed Paraffin-Embedded Gliomas Using Multiplex PCR and Single-base Extension.
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
IDH1 mutations in gliomas: when an enzyme loses its grip.
IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Immunohistochemical and molecular genetics study of a granular cell astrocytoma: A case report of malignant transformation to a glioblastoma.
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.
Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer.
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery.
Intraventricular Glioblastomas.
Isocitrate Dehydrogenase (IDH) Inhibition as Treatment of Myeloid Malignancies: Progress and Future Directions.
Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.
Isocitrate dehydrogenase mutations in myeloid malignancies.
Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Isoenzymes of isocitrate dehydrogenase in cytoplasm of human cancer cells.
L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
Low-grade gliomas.
Magnetic resonance metabolic imaging of glioma.
Metabolic modulation of cancer: a new frontier with great translational potential.
Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity.
Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel.
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells.
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
Mutant IDH is sufficient to initiate enchondromatosis in mice.
Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors.
Myeloproliferative neoplasms: Current molecular biology and genetics.
Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases.
Papillary tumor of the pineal region: a case involving isocitrate dehydrogenase (IDH) genotyping.
Papilloedema secondary to oligodendroglioma.
Pediatric glioblastoma with oligodendroglioma component: Aggressive clinical phenotype with distinct molecular characteristics.
Photoactivation of Mutant Isocitrate Dehydrogenase 2 Reveals Rapid Cancer-Associated Metabolic and Epigenetic Changes.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Protein Markers Predict Survival in Glioma Patients.
Proteomic profiling of differential display analysis for human oral squamous cell carcinoma: 14-3-3 ? Protein is upregulated in human oral squamous cell carcinoma and dependent on the differentiation level.
Proximity ligation assay evaluates IDH1R132H presentation in gliomas.
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Rare insights into cancer biology.
Reasons for optimism in the therapy of acute leukemia.
Recent aspects of classification and epidemiology of epilepsy-associated tumors.
Revisiting the TCA cycle: signaling to tumor formation.
Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
Role of mitochondrial dysfunction in cancer progression.
Roles of IDH1/2 and TET2 mutations in myeloid disorders.
Sclerosing stromal tumor of the ovary. A light, electron microscopic and enzyme histochemical study.
Single arginine mutation in two yeast isocitrate dehydrogenases: biochemical characterization and functional implication.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Studies on the isocitrate dehydrogenase. II. Isocitrate dehydrogenase and transhydrogenase in tumor bearing rat liver and ascites tumor cells.
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Targeting cancer metabolism.
Targeting isocitrate dehydrogenase (IDH) in cancer.
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State.
Ten-Eleven Translocation-2 gene mutations: A potential new molecular marker in malignant gliomas (Review).
TET proteins and the control of cytosine demethylation in cancer.
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
The studies on glycolytic enzymes in relation to cancer. II. Comparative study of phosphohexose-isomerase, aldolase, isocitric dehydrogenase, serum glutamic oxaloacetic and pyruvic transaminase, and alkaline phosphatase in liver.
Therapeutic effect of tamoxifen and energy-modulating vitamins on carbohydrate-metabolizing enzymes in breast cancer.
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Treatment Strategies for Low-Grade Glioma in Adults.
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells.
Update on molecular findings, management and outcome in low-grade gliomas.
Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism.
World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages.
[Activity of isocitrate dehydrogenase in breast cancer]
[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].
[Isomerase phosphohexose, isocitric dehydrogenase, and alkaline phosphatase in cancer patients]
[Research on molecular markers for epigenetic changes in myeloid malignancies].
[Studies on the recording of cytostatic effects on organ cultures of squamous cell carcinoma of the uterine cervix]
Nephrotic Syndrome
Activity of serum enzymes in puromycin aminonucleoside-induced nephrotic syndrome.
Nervous System Diseases
Isocitric dehydrogenase activity of the cerebrospinal fluid of children with neurologic disorders.
Neuroblastoma
Mitochondrial isocitrate dehydrogenase protects human neuroblastoma SH-SY5Y cells against oxidative stress.
Obesity
Increased obesity resistance and insulin sensitivity in mice lacking the isocitrate dehydrogenase 2 gene.
Oligodendroglioma
Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry.
Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.
Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas.
Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.
Molecular subclassification of diffuse gliomas: Seeing order in the chaos.
Mutant metabolic enzymes are at the origin of gliomas.
Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity.
Promoter Methylation Analysis of IDH Genes in Human Gliomas.
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Osteosarcoma
A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Pancreatic Neoplasms
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Paraganglioma
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Peptic Ulcer
Isocitrate Dehydrogenase of Helicobacter pylori Potentially Induces Humoral Immune Response in Subjects with Peptic Ulcer Disease and Gastritis.
Periodontitis
Expression of TET2 enzyme indicates enhanced epigenetic modification of cells in periodontitis.
Pheochromocytoma
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.
Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
Prostatic Hyperplasia
Isocitrate dehydrogenase activity in untreated and treated benign prostatic hypertrophy and adenocarcinomatous prostate.
Prostatic Neoplasms
Modulation of hypoxia-inducible factor-1? expression by mitochondrial NADP(+)-dependent isocitrate dehydrogenase.
Targeting cancer metabolism.
Psoriasis
Epidermal activity of NAD-dependent isocitrate dehydrogenase in psoriasis during treatment with dithranol.
Isozymes of NADP-linked isocitric dehydrogenase in psoriasis and human basal cell carcinoma.
Pyelonephritis
[Serum and urine isocitrate dehydrogenase activity in patients with chronic pyelonephritis]
Reperfusion Injury
Mitochondrial NADP(+)-Dependent Isocitrate Dehydrogenase Deficiency Exacerbates Mitochondrial and Cell Damage after Kidney Ischemia-Reperfusion Injury.
Retinoblastoma
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Reye Syndrome
Serum isocitrate dehydrogenase activity in Reye's syndrome.
Sarcoma
Targeting cancer metabolism.
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Schistosomiasis
Serum isocitric dehydrogenase and glutamic dehydrogenase in schistosomiasis.
Seizures
IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients.
Seminoma
Modified expression of cytoplasmic isocitrate dehydrogenase electrophoretic isoforms in seminal plasma of men with sertoli-cell-only syndrome and seminoma.
Shock, Septic
[The effect of vitamin E on the survival rate and biochemical parameters such as isocitrate dehydrogenase, lactate and selected peptidases and proteases during endotoxic shock in the rat]
Starvation
Biochemical characterization of NADP(+)-dependent isocitrate dehydrogenase from Microcystis aeruginosa PCC7806.
Metabolic and ultrastructural responses of lupine embryo axes to sugar starvation.
Physiological regulation of isocitrate dehydrogenase and the role of 2-oxoglutarate in Prochlorococcus sp. strain PCC 9511.
Stomach Neoplasms
Flow-cytometric determination of dehydrogenase activities in primary human gastrointestinal tumor cell lines.
Isocitrate Dehydrogenase 2 Dysfunction Contributes to 5-hydroxymethylcytosine Depletion in Gastric Cancer Cells.
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer.
Tauopathies
Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis.
Thyroid Neoplasms
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Targeting cancer metabolism.
Tuberculosis
Cloning, expression, purification, crystallization and preliminary X-ray crystallographic analysis of isocitrate dehydrogenase 2 (Rv0066c) from Mycobacterium tuberculosis.
Comparison of Mycobacterium tuberculosis isocitrate dehydrogenases (ICD-1 and ICD-2) reveals differences in coenzyme affinity, oligomeric state, pH tolerance and phylogenetic affiliation.
Development of mycobacterial species-specific DNA probes by subtraction hybridization.
Further studies with isocitric dehydrogenase in experimental tuberculosis: influence of isoniazid on metabolic damage.
Identification, molecular cloning, and evaluation of potential use of isocitrate dehydrogenase II of Mycobacterium bovis BCG in serodiagnosis of tuberculosis.
Isocitric dehydrogenase and nicotinamide adenine dinucleotidase in experimental tuberculosis: influence of isoniazid on metabolic damage.
Purification and characterisation of isocitrate dehydrogenase and malate dehydrogenase from Mycobacterium tuberculosis and evaluation of their potential as suitable antigens for the serodiagnosis of tuberculosis.
Urinary Bladder Neoplasms
Identification of differentially expressed proteins during human urinary bladder cancer progression.
Uterine Hemorrhage
Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium.
Viremia
Acute GB virus B infection of marmosets is accompanied by mutations in the NS5A protein.
Weil Disease
[The value of isocitric dehydrogenase in the differential diagnosis between viral hepatitis and Weil's disease.]
Whooping Cough
A Functional Tricarboxylic Acid Cycle Operates during Growth of Bordetella pertussis on Amino Acid Mixtures as Sole Carbon Substrates.